Carotuximab Reference: HY-P99494 Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions.
Olamkicept Reference: HY-P99766 Olamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 (sIL-6R)/IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent.
Itolizumab Reference: HY-P99252 Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
Belimumab Reference: HY-P9952 Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research.
Tepoditamab Reference: HY-P99390 Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research.
Briobacept Reference: HY-P99487 Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA).
Asunercept Reference: HY-P99445 Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).
Regavirumab Reference: HY-P99824 Regavirumab (MCA C23) is a human monoclonal antibody against cytomegalovirus (CMV), human serum albumin (HSA) and amino acetic acid.
(2S,5S)-Censavudine Reference: HY-16776A (2S,5S)-Censavudine ((2S,5S)-OBP-601) is the (2S,5S)-enantiomer of Censavudine. Censavudine, a nucleoside reverse transcriptase inhibitor, is a potent HIV inhibitor.
Pegdinetanib Reference: HY-P99826 Pegdinetanib (BMS-844203; CT-322) is a selective VEGFR-2 (VEGFR) inhibitor with Kds of 11 nM and 250 nM and IC50s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity.
Netakimab Reference: HY-P99754 Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis.
Naptumomab estafenatox Reference: HY-P99749 Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer.